MSB 1.10% 91.5¢ mesoblast limited

To add to that - Patients that are eligible for the Molecular...

  1. 494 Posts.
    lightbulb Created with Sketch. 251
    To add to that -

    Patients that are eligible for the Molecular “EMPATHY” trial must be experiencing a minimum of two predetermined mild or moderate symptoms within a week prior to diagnosis. – these symptoms may be respiratory related but respiratory is not singled out and could be plethora of others.

    The trial is aiming to prevent worsening symptoms and hospitalization for patients in the early stages of the of infection.

    Below is the link to the announcement on the Novartis website. Respiratory was not once mentioned throughout the text.

    https://www.novartis.com/news/media-releases/novartis-and-molecular-partners-announce-start-empathy-clinical-trial-ensovibep-treatment-covid-19








 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
91.5¢
Change
0.010(1.10%)
Mkt cap ! $1.044B
Open High Low Value Volume
93.0¢ 93.5¢ 90.5¢ $4.638M 5.036M

Buyers (Bids)

No. Vol. Price($)
9 152669 91.0¢
 

Sellers (Offers)

Price($) Vol. No.
92.5¢ 51069 3
View Market Depth
Last trade - 16.10pm 07/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.